Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
Tan, Antoinette R, Im, Seock-Ah, Mattar, André, Colomer, Ramon, Stroyakovskii, Daniil, Nowecki, Zbigniew, De Laurentiis, Michelino, Pierga, Jean-Yves, Jung, Kyung Hae, Schem, Christian, Hogea, Alexandra, Badovinac Crnjevic, Tanja, Heeson, Sarah, Shivhare, Mahesh, Kirschbrown, Whitney P, Restuccia, Eleonora, Jackisch, Christian
Published in The lancet oncology (01.01.2021)
Published in The lancet oncology (01.01.2021)
Get full text
Journal Article
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
Kirschbrown, Whitney P., Wynne, Chris, Kågedal, Matts, Wada, Russ, Li, Hanbin, Wang, Bei, Nijem, Ihsan, Badovinac Crnjevic, Tanja, Gasser, Helena, Heeson, Sarah, Eng‐Wong, Jennifer, Garg, Amit
Published in Journal of clinical pharmacology (01.05.2019)
Published in Journal of clinical pharmacology (01.05.2019)
Get full text
Journal Article
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
Quartino, Angelica L., Li, Hanbin, Kirschbrown, Whitney P., Mangat, Ranvir, Wada, D. Russell, Garg, Amit, Jin, Jin Y., Lum, Bert
Published in Cancer chemotherapy and pharmacology (01.02.2019)
Published in Cancer chemotherapy and pharmacology (01.02.2019)
Get full text
Journal Article
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
Liu, Stephanie N., Lu, Tong, Jin, Jin Y., Li, Chunze, Girish, Sandhya, Melnikov, Fjodor, Badovinac Crnjevic, Tanja, Machackova, Zuzana, Restuccia, Eleonora, Kirschbrown, Whitney P.
Published in Journal of clinical pharmacology (01.08.2021)
Published in Journal of clinical pharmacology (01.08.2021)
Get full text
Journal Article
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.
Published in Cancer chemotherapy and pharmacology (01.09.2021)
Published in Cancer chemotherapy and pharmacology (01.09.2021)
Get full text
Journal Article
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
Kirschbrown, Whitney P., Wang, Bei, Nijem, Ihsan, Ohtsu, Atsushi, Hoff, Paulo M., Shah, Manish A., Shen, Lin, Kang, Yoon-Koo, Alsina, Maria, Girish, Sandhya, Garg, Amit
Published in Cancer chemotherapy and pharmacology (01.09.2019)
Published in Cancer chemotherapy and pharmacology (01.09.2019)
Get full text
Journal Article
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.
Published in Cancer chemotherapy and pharmacology (01.04.2022)
Published in Cancer chemotherapy and pharmacology (01.04.2022)
Get full text
Journal Article
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
Luo, Yang, Li, Wei, Jiang, Zefei, Zhang, Qingyuan, Wang, Liwei, Mao, Yixiang, Tjan-Heijnen, Vivianne C G, Im, Seock-Ah, McConnell, Robin, Bejarano, Sara, Fumagalli, Debora, Bines, José, Wang, Bei, Garg, Amit, Kirschbrown, Whitney P, Xu, Binghe
Published in Anti-cancer drugs (01.09.2019)
Published in Anti-cancer drugs (01.09.2019)
Get more information
Journal Article
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Kirschbrown, Whitney P., Kågedal, Matts, Wang, Bei, Lindbom, Lars, Knott, Adam, Mack, Rachelle, Monemi, Sharareh, Nijem, Ihsan, Girish, Sandhya, Freeman, Christie, Fumagalli, Debora, McConnell, Robin, Jerusalem, Guy, Twelves, Chris, Baselga, José, von Minckwitz, Gunter, Bines, José, Garg, Amit
Published in Cancer chemotherapy and pharmacology (01.06.2019)
Published in Cancer chemotherapy and pharmacology (01.06.2019)
Get full text
Journal Article
Web Resource
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, 3rd, Howard A, Zamboni, William C
Published in International journal of nanomedicine (01.01.2015)
Published in International journal of nanomedicine (01.01.2015)
Get full text
Journal Article
Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study
Tan, Antoinette R, Im, Seock-Ah, Mattar, Andre, Colomer, Ramon, Stroyakovskii, Daniil, Nowecki, Zbigniew, De Laurentiis, Michelino, Pierga, Jean-Yves, Jung, Kyung Hae, Schem, Christian, Heeson, Sarah, Shivhare, Mahesh, Kirschbrown, Whitney P., Restuccia, Eleonora, Crnjevic, Tanja Badovinac, Jackisch, Christian
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy
Daver, Naval G., Garcia, Jacqueline S, Jonas, Brian A, Kelly, Kevin R, Assouline, Sarit, Brandwein, Joseph M, Fenaux, Pierre, Olin, Rebecca L., Martinelli, Giovanni, Paolini, Stefania, Pigneux, Arnaud, Pollyea, Daniel A, Powell, Bayard L, Roboz, Gail J., Tafuri, Agostino, Vey, Norbert, Visani, Giuseppe, Yee, Karen W.L., Dail, Monique, Green, Cherie, Kirschbrown, Whitney P, Hong, Wan-Jen, Ott, Marion G, Onishi, Maika, Wang, Jue, Konopleva, Marina Y, Andreeff, Michael
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Wu, Huali, Infante, Jeffrey, Keedy, Vicki, Jones, Suzanne, Chan, Emily, Bendell, Johanna, Lee, Wooin, Caron, Whitney, Zamboni, Beth, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace, Burris III, Howard, Zamboni, William
Published in International journal of nanomedicine (01.07.2019)
Published in International journal of nanomedicine (01.07.2019)
Get full text
Journal Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan in patients with advanced solid tumors
Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, III, Howard A, Zamboni, William C
Published in International journal of nanomedicine (01.01.2015)
Published in International journal of nanomedicine (01.01.2015)
Get full text
Journal Article